“Palo Alto-based Neu­ro­track, which has devel­oped an online cog­ni­tive assess­ment test, raised $6.5 mil­lion in a round led by Khosla Ven­tures with par­tic­i­pa­tion from Social Cap­i­tal, Founders Fund, AME Cloud Ven­tures, and iSeed Ven­tures. This brings Neurotrack’s total fund­ing to $9.5 mil­lion.

Neu­ro­track has devel­oped two offer­ings. The first is a five minute, web-based test, called Imprint Cog­ni­tive Assess­ment Test that eval­u­ates whether a patient is at risk for Alzheimer’s…The company’s oth­er prod­uct, which will work in con­junc­tion with Imprint, is a web or app-based cog­ni­tive health inter­ven­tion pro­gram that aims to help improve a user’s cog­ni­tive health…

While many are focused on find­ing a drug for Alzheimer’s, Kaplan said there’s oth­er impor­tant work to be done too.

“As a result of this focus on get­ting to a drug, find­ing a drug — which is incred­i­bly impor­tant, and we don’t want to lose sight of it — we have over­looked a real­ly impor­tant body of sci­en­tif­ic evi­dence com­ing out of Europe, US, oth­er places that have shown that it’s pos­si­ble to actu­al­ly pre­vent cog­ni­tive decline using very spe­cif­ic changes in diet, exer­cise, cog­ni­tive train­ing, man­ag­ing your sleep, and man­ag­ing your stress lev­els,” Kaplan said.

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.